BioCentury
ARTICLE | Clinical News

Boehringer reports SVR12 data for all-oral HCV regimen

June 14, 2013 12:22 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) reported data from the Phase IIb SOUND-C3 trial evaluating an all-oral regimen that included the company's faldaprevir and deleobuvir to treat chronic HCV genotype 1 infection in treatment-naïve patients. In the open-label trial, 19 of 20 (95%) evaluable patients who received once-daily faldaprevir ( BI 201335) plus twice-daily deleobuvir ( BI 207127) and ribavirin for 16 weeks achieved a sustained virologic response (SVR) 12 weeks after the end of treatment, including all four patients with liver cirrhosis. Data were presented at the Asian Pacific Association for the Study of the Liver meeting in Singapore. ...